Skip Navigation LinksHome > December 2008 - Volume 21 - Issue 4 > Clinical Trial Design Issues in Mild to Moderate Alzheimer D...
Text sizing:
Cognitive & Behavioral Neurology:
doi: 10.1097/WNN.0b013e318190cf75
Review Article

Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease

Knopman, David S. MD

Collapse Box


The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.